TARS Q4 2023 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M+30.8% YoY

Gross Profit

$12M90.7% margin

Operating Income

-$44M-339.9% margin

Net Income

-$42M-320.4% margin

EPS (Diluted)

$-1.31

QoQ Revenue Growth

+598.9%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$39M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$265M

Total Liabilities

$69M

Stockholders' Equity

$197M

Cash & Equivalents

$225M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$10M	+30.8%
Gross Profit	$12M	$10M	+23.5%
Operating Income	-$44M	-$15M	-195.1%
Net Income	-$42M	-$14M	-208.1%

Revenue Segments

Product

$13M100%